Enfusion

Enfusion, Inc. engages in the development of cloud-native multi-tenant software for alternative and institutional investment managers. It is a software-as-a-service firm that develops a platform to eliminate technology and information barriers, and simplify investment and operational workflows by unifying mission-critical systems and coalescing data into a single dataset. The company was founded by Tarek Hammoud, Stephen M. Malherbe, Oleg Movchan, and Scott Werner in 2006 and is headquartered in Chicago, IL.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Enfusion reports robust Q4 earnings, eyes growth in new markets

Enfusion's Q4 2022 performance reflects financial strength and growth momentum, supported by revenue growth, client wins, and strategic guidance for 2023.
The company's strengths lie in its market positioning, regional focus, and commitment to innovation, while challenges include managing churn levels and scaling managed services profitably.
Opportunities in expanding into new markets, enhancing client relationships, and driving revenue growth through strategic initiatives position Enfusion for continued success and market leadership.
Overall, Enfusion's proactive approach to market dynamics, client services, and product development sets a solid foundation for sustained growth and value creation, aligning with investor expectations and industry trends.

Enfusion reports robust Q1 earnings, eyes growth amid market challenges

Enfusion's Q1 2023 Earnings Call highlighted strong financial performance, strategic partnerships, and a positive outlook for the year. Despite market challenges, the company remains resilient and focused on growth opportunities. Management's reaffirmation of guidance and optimism for the future reflect confidence in Enfusion's trajectory.

Enfusion reports strong Q2 earnings, eyes growth through strategic partnerships

Enfusion's Q2 performance showcased growth and profitability despite challenges. The company's strategic focus on efficiency, partnerships, and tailored pricing strategies bodes well for future expansion and revenue generation.

Enfusion reports robust Q3 performance and eyes sustainable 20% growth

Enfusion's Q3 performance showcased strong revenue growth, client additions, and global market expansion, with a focus on Portfolio WorkBench.
Confidence in reaffirmed guidance, positive organic growth trends, and strategic investments position Enfusion for sustained success.
Challenges include managing quarterly fluctuations, balancing investments for growth, and addressing strategic clarity in key areas.
Opportunities lie in leveraging product capabilities, targeted investments, ACV growth, and global market expansion for continued success.

Enfusion reports robust Q4 earnings, eyes growth through technology innovation

Enfusion's strong Q4 performance, focus on SaaS platform benefits, and strategic guidance for 2024 demonstrate a commitment to growth and innovation. The company's emphasis on client service, technology enhancements, and market opportunities positions them well for future success. Enfusion's Investor Day in Fort Lauderdale on March 19 will showcase their integrated investment technology platform and growth outlook.

Enfusion excels in Q1 performance, eyes growth through client focus

Enfusion's Q1 2024 performance showcased strong revenue growth, client wins, and margin expansion, driven by efficient client onboarding and product enhancements.
The company's strengths in client relationships, differentiated offerings, and strategic pricing position it well for future growth and value creation.
Challenges in client fee pressure, resource allocation, and evolving seasonality require strategic solutions, while opportunities in product enhancements and growth algorithm offer avenues for expansion.
Enfusion's commitment to delivering on promises, shareholder value creation, and differentiation underpin its optimistic outlook and focus on long-term success.

Enfusion reports robust Q2 earnings, eyes global expansion opportunities

Enfusion's Q2 performance reflects strong revenue growth, client acquisitions, and product innovation.
The company's resilience to market forces and global expansion efforts position it for continued success.
Challenges lie in maintaining growth momentum, deepening client relationships, and adapting to market dynamics.

Enfusion reports robust Q3 growth, eyes sustained expansion and innovation

Enfusion's Q3 2024 earnings call highlighted strong financial performance, client acquisitions, and product advancements. The company's tightened revenue and EBITDA guidance for 2024 reflects management's confidence in continued growth. Analyst inquiries centered on strategic alternatives, product innovations, and revenue drivers, indicating investor interest in Enfusion's future prospects.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Enfusion, Inc. (NYSE:ENFN ) Q3 2024 Earnings Conference Call November 4, 2024 8:30 AM ET Company Participants Bill Wright - Head, IR Oleg Movchan - Chief Executive Officer Bradley Herring - Chief Financial Officer Neal Pawar - Chief Operating Officer Conference Call Participants Michael Infante - Morgan Stanley Dylan Becker - William Blair Parker Lane - Stifel Kevin McVeigh - UBS Elise Kenner - JP Morgan Gabriela Borges - Goldman Sachs Koji Ikeda - Bank of America Crispin Love - Piper Sandler Operator Good morning, ladies and gentlemen. Thank you for standing by.

Enfusion, Inc. (ENFN) Q3 2024 Earnings Call Transcript

The headline numbers for Enfusion (ENFN) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Here's What Key Metrics Tell Us About Enfusion (ENFN) Q3 Earnings

Enfusion, Inc. (ENFN) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.04 per share a year ago.

Enfusion, Inc. (ENFN) Q3 Earnings and Revenues Miss Estimates

NEW YORK & LONDON & HONG KONG--(BUSINESS WIRE)--Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, has posted its third quarter 2024 financial results as part of its Q3 2024 Shareholder Letter which can be viewed by navigating to the Financials section of its Investor Relations website at http://ir.enfusion.com. 3Q24 Earnings Conference Call Management will host a conference call today, November 4, 2024, at 8:30 AM ET.

Enfusion Announces Third Quarter 2024 Results

NEW YORK--(BUSINESS WIRE)--Enfusion, Inc. (“Enfusion”) (NYSE: ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, announced today the appointments of Arman Artuc to Head of Engineering and Jesper Cordes to Head of Client Services Americas. These additions to the leadership team reinforce the company's position as a global leader in investment technology and services, which enables Enfusion to continue to attract top-performing industry experts and innova.

Enfusion Announces Key Leadership Team Additions to Drive Client Success and Fuel Innovation

Globant

SAN FRANCISCO & RUTHERFORD, Calif.--(BUSINESS WIRE)--FTV Capital, a leading sector-focused growth equity firm, and One Mind at Work, a global nonprofit dedicated to building the future of workforce mental health, today announced a first-of-its-kind partnership to advance mental health and wellbeing within high-growth companies in the FTV portfolio. The expanded partnership coincides with World Mental Health Day, which is highlighting workplace mental health as its official 2024 theme. Over the.

FTV Capital and One Mind at Work Launch Partnership to Support Mental Health Within High-Growth Companies

NEW YORK & LONDON & HONG KONG--(BUSINESS WIRE)--Enfusion, Inc. ("Enfusion") (NYSE: ENFN), a leading provider of software-as-a-service (SaaS) solutions for investment managers, today announced it will release its third quarter 2024 financial results before the U.S. financial markets open on Monday, November 4, 2024. Management will host a conference call and webcast that same morning at 8:30 AM (ET) / 5:30 AM (PT) to discuss the results. To access this call, dial (888) 596-4144. The conference I.

Enfusion Announces Date of Third Quarter 2024 Results

LOS ANGELES, CA / ACCESSWIRE / October 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites Investor Participation In An Inquiry Into Enfusion Inc For Violating Securities Laws

LOS ANGELES, CA / ACCESSWIRE / October 1, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Enfusion, Inc. Is Being Looked Into For Possible Securities Fraud And Affected Shareholders Are Urged To Contact The Schall Law Firm

LOS ANGELES, CA / ACCESSWIRE / September 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites Investors To Help Investigate Whether Enfusion Inc Violated Securities Laws

NEW YORK, NY / ACCESSWIRE / September 29, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or the "Company") (NYSE: ENFN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enfusion, Inc. - ENFN

LOS ANGELES, CA / ACCESSWIRE / September 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into Enfusion, Inc. For Possible Securities Fraud

LOS ANGELES, CA / ACCESSWIRE / September 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Enfusion Inc Is Being Investigated For Violating Securities Laws And The Schall Law Firm Seeks Investor Participation

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Inquiring Into Enfusion, Inc. For Possible Securities Fraud And Stockholders With Losses Should Take Part

LOS ANGELES, CA / ACCESSWIRE / September 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Enfusion Inc May Have Violated Securities Laws And The Schall Law Firm Wants Impacted Investors To Reach Out

LOS ANGELES, CA / ACCESSWIRE / September 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Shareholders Are Urged To Join The Schall Law Firm's Investigation Into Enfusion, Inc. For Possible Securities Fraud

BRISBANE, Australia--(BUSINESS WIRE)--VALD, a global health technology company and the system of choice for musculoskeletal (“MSK”) health professionals, today announced a significant growth equity investment from FTV Capital, a sector-focused growth equity firm. The investment will enable VALD to grow its global team into new markets, launch new product offerings and capabilities, and continue to utilize AI to create unique applications for the company's industry-leading, proprietary dataset o.

VALD Secures Significant Growth Equity Investment from FTV Capital

LOS ANGELES, CA / ACCESSWIRE / September 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Enfusion Inc Is Being Looked Into For Violating Securities Laws And The Schall Law Firm Invites Investors To Reach Out

Enfusion (ENFN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Enfusion (ENFN) Moves 5.0% Higher: Will This Strength Last?

LOS ANGELES, CA / ACCESSWIRE / September 23, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Investigating Enfusion, Inc. For Possible Securities Fraud And Affected Shareholders Are Urged To Lend A Hand

LOS ANGELES, CA / ACCESSWIRE / September 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Enfusion Inc May Have Violated Securities Laws And The Schall Law Firm Wants Investors With Losses To Help With An Inquiry

LOS ANGELES, CA / ACCESSWIRE / September 21, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Is Looking Into Enfusion, Inc. For Possible Securities Fraud And Shareholders Are Urged To Take Part

Enfusion , a U.S. software provider for asset managers, is in talks with investment bankers to evaluate its options that could include a potential sale, according to people familiar with the matter.

Exclusive: Financial software maker Enfusion explores options including sale, sources say

LOS ANGELES, CA / ACCESSWIRE / September 20, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Enfusion Inc May Have Violated Securities Regulations And The Schall Law Firm Encourages Investor Participation In An Inquiry

LOS ANGELES, CA / ACCESSWIRE / September 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

News for Enfusion Stock (ENFN)